Hypomethylation within this gene in CLL patients with SF3B1 mutation has been previously reported [23] and it has been recently shown that BCL9 and BCL9L promote tumorigenicity in a triple negative breast cancer mouse model through immune-dependent (TGF-β) and immune-independent (Wnt) pathways [90]. This evidence concerns the gene BCL9L and B-cell chronic lymphocytic leukemia.